Clinical Data — Investor Presentation (November 2005)
20 slides from Clinical Data's investor presentation, Nov 8, 2005
Slide 1: Investor Presentation October, 2005
Investor Presentation October, 2005
Slide 2: Forward-Looking Statements
Forward-Looking Statements SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 The following presentation contains certain forward-looking information about Clinical Data that are intended to be covered by the safe harbor for "forward-looking statements" provided by the
Slide 3: Clinical Data: Leader in pharmacogenomics and clinical diagnostics
Clinical Data Leader in commercializing pharmacogenomics and clinical diagnostics Strategic focus - genetics for efficient drug utilization - a multi- billion dollar opportunity
Slide 4: Investment Highlights
Investment Highlights Market leader in commercializing pharmacogenomics to pharma/biotech Late stage proprietary pharmacogenomic product pipeline targeting clinical marketplace Business strategy provides sustainability with significant upside potential World-wide revenues approximately $90M (pro-for
Slide 5: Clinical Data Historic Business
Clinical Data Historic Business Global Sales to Physician Office Labs and Clinics of: Chemistry and Hematology analyzers Laboratory reagents and supplies Laboratory management and consulting services Consistently profitable core business $52.9 million in revenue (TTM) $ 4.3 million operating income
Slide 6: Services/Laboratory Business
Services/Laboratory Business Leading provider of GLP & research DNA/RNA analysis services CLIA regulated laboratories US/UK operations and global sales force Strong growth across multiple markets: pharmaceutical, agricultural, government and consumer Applicable to all disease areas including oncolog
Slide 7: Leveraging Core Business
Leveraging Core Business Addition of Genaissance and Icoria adds: Leading independent pharmacogenomic and metabolomic services business Cost advantages and economies of scale High margin, proprietary molecular services businesses Core businesses foundation for innovations around therapy optimization
Slide 8: Regulators and Industry Support Pharmacogenomics
Regulators and Industry Support Pharmacogenomics FDA defining the regulatory terrain: Guidance for Pharmacogenomic Data Submissions issued 2005 Builds on early examples: Herceptin, Gleevec and Erbitux Goal is to speed development of new drugs CMS, FDA and other Payors strongly supportive Growing acc
Slide 9: Comprehensive Genomics Services Business
Comprehensive Genomics Services Business Sequencing Genotyping Molecular Sciences Gene Expression/Pathway Analysis Extraction and BioBanking Research Phase Clinical Dev. Preclinical Dev. Post Launch Product Lifecycle Supports development of BioMarkers and Clinical PGx Products
Slide 10: BioMarkers Change the Drug Response Paradigm
BioMarkers Change the Drug Response Paradigm Efficacy/safety is enriched through patient selection Drug Response Number of Patients Conventional Drugs PGx/Rx Products
Slide 11: Product Pipeline: TPMT Test for Drug Toxicity
TPMT Test for Drug Toxicity Marketed Marketed Goal: Apply to a Partner's Drug Drug-Induced Long QT Test In Development Test Marketed Expand sales PGx/Rx Depression Combination Initiate Phase II Plan PGx/Rx trial Product Pipeline 2005 2006 Partner Commence Commercialization Clozapine PGx Validation s
Slide 12: Proprietary Molecular Test: Cardiac Channelopathies
Proprietary Molecular Test Inherited disorders caused by mutations in ion channel genes: Long QT Syndrome Brugada Syndrome Arrhythmias in seemingly healthy and young individuals: Sudden cardiac death About 100,000 carriers in U.S. Cardiac Channelopathies:
Slide 13: Proprietary Molecular Test
Proprietary Molecular Test CLIA compliant test launched May 2004 Initial focus: 300 pediatric cardiologists/electrophysiologists in U.S. Internal sales force Leverage ten years of data and existing need Guides treatment options and provides clarity for other family members Over 150 patient referrals
Slide 14: Drug-Induced Long QT Test
Drug-Induced Long QT Test Major problem for pharma: >50 approved drugs prolong QT interval Major drugs (e.g., Seldane, Propulsid) withdrawn due to QT prolongation Clinical Data strategy: Use the FAMILION(tm) Test for clinical trials Use our HAP(tm)-Based Drug Response Engine to expand into drug-indu
Slide 15: CARING: Expanding Clozapine for Schizophrenia
CARING: Expanding Clozapine for Schizophrenia Clinical issues Gold standard but requires regular monitoring Objective PGx/Rx combination prospectively identifies patients likely to develop life- threatening adverse effects Progress to date Case control study DNA samples from 70 patients collected Po
Slide 16: Vilazodone
Vilazodone Primary Indication: Treatment of depression PGx/Rx Profile: PGx: Qualification of SSRI/5HT1A responders through proprietary PGx Rx: New generation dual serotonergic antidepressant Mechanism of Action: RX: A unique molecule, both a Selective Serotonin Reuptake Inhibitor (SSRI) and a 5HT1A
Slide 17: Major Relationships - Services Collaborations/I.P.
Major Relationships - Services Collaborations/I.P.
Slide 18: Upcoming Milestones
Upcoming Milestones Complete recruitment of senior management team Focus Genomic Services Business Expand adoption of the FAMILION(tm) Test Launch of Clozapine molecular test - Mid 2006 Commence Phase II clinical trial for vilazodone in H1 2006 Expand proprietary test pipeline Additional industry-le
Slide 19: Investment Highlights: In Summary
Investment Highlights Market leader in commercializing pharmacogenomics to pharma/biotech Late stage proprietary pharmacogenomic product pipeline targeting clinical marketplace Business strategy provides sustainability with significant upside potential World-wide revenues approximately $90M (pro-for
Slide 20: Clinical Data
Clinical Data‘ Investor Presentation
Clinical Data — Investor Presentation (November 2005) on 6ix